ERBB2 and gastric cancer: In 2010, the ToGA trial demonstrated that trastuzumab, an anti-human epidermal growth factor receptor-2 (HER2) monoclonal antibody, with systemic chemotherapy improved the survival of patients with HER2-positive advanced GC [7].